The absence of effect of imatinib administration by the prevention (gavage) and treatment (intravesical infusion) on mechanical sensitivity in mice with acute CYP-induced cystitis may suggest that imatinib mesylate may be more appropriate as a treatment for OAB where patients present with urinary storage symptoms (e.g., increased urgency, frequency, nocturia) without pelvic pain, pressure or discomfort reported by IC/BPS patients (Macdiarmid and Sand, 2007). This evidence concerns the gene PPIG and chronic cystitis.